title: Comparative therapeutic effect of probiotic Lactobacillus casei alone and in conjunction with antiprotozoal drugs in murine giardiasis.
abstract: Various antiprotozoal drugs have been used to counteract the spread of giardiasis. However, due to increase in resistance to these compounds, there is an urgent need to find a natural biocompatible product to fight the pathogen in more healthy and effective way. The present study was designed to compare the therapeutic effect of probiotic Lactobacillus casei alone and in conjunction with antiprotozoal drugs on the outcome of giardiasis in murine model. BALB/c mice were challenged with Giardia intestinalis trophozoites, and 1 day after infection, these mice were treated with either probiotic alone or in conjunction with antiprotozoal drugs. Cyst, trophozoite, and lactobacilli counts were monitored vis-a-vis histopathological alterations in the small intestine. It was found that albendazole administered orally 1 day after Giardia infection was the most effective antiprotozoal drug among albendazole, tinidazole, metronidazole, and nitazoxanide. It reduced both the severity and duration of giardiasis. More specifically, oral administration of the probiotic L. casei in conjunction with albendazole further reduced the Giardia infection as was evident by the restored normal gut morphology. This suggests that probiotics and antiprotozoal drugs in combination may be the better alternative therapy for treatment of gastrointestinal diseases and enhanced recovery.
authors.affiliation: Department of Microbiology, Panjab University, Basic Medical Sciences Building, Chandigarh, 160014, India. geeta_shukla@pu.ac.in
authors.forename: Geeta
authors.initials: G
authors.lastname: Shukla
authors.forename: Hemjeet
authors.initials: H
authors.lastname: Kaur
authors.forename: Lalita
authors.initials: L
authors.lastname: Sharma
mesh_terms: D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination / Q000379:methods; D016829:Giardia lamblia / Q000302:isolation & purification; D005873:Giardiasis / Q000188:drug therapy* / Q000469:parasitology / Q000473:pathology; D006651:Histocytochemistry; D007421:Intestine, Small / Q000473:pathology; D007780:Lacticaseibacillus casei / Q000254:growth & development*; D051379:Mice; D008807:Mice, Inbred BALB C; D019936:Probiotics / Q000008:administration & dosage*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000981:Antiprotozoal Agents
references.citation: Infect Immun. 2005 Feb;73(2):1265-9
references.pmid: 15664978
references.citation: Infect Immun. 2000 Feb;68(2):752-9
references.pmid: 10639443
references.citation: Microb Pathog. 1991 May;10(5):343-50
references.pmid: 1836523
references.citation: Curr Pharm Des. 2003;9(2):175-91
references.pmid: 12570667
references.citation: J Nutr. 2005 May;135(5):1171-6
references.pmid: 15867299
references.citation: Clin Microbiol Rev. 2001 Jan;14(1):150-64
references.pmid: 11148007
references.citation: Phytother Res. 1999 Nov;13(7):561-5
references.pmid: 10548746
references.citation: Aliment Pharmacol Ther. 1994 Apr;8(2):187-92
references.pmid: 8038350
references.citation: Lancet. 1997 May 24;349(9064):1498-504
references.pmid: 9167458
references.citation: Antimicrob Agents Chemother. 1985 Feb;27(2):227-9
references.pmid: 3985604
references.citation: J Antimicrob Chemother. 2000 Nov;46(5):819-21
references.pmid: 11062206
references.citation: Aliment Pharmacol Ther. 2002 Mar;16(3):587-93
references.pmid: 11876714
references.citation: Fundam Clin Pharmacol. 2003 Apr;17(2):189-97
references.pmid: 12667229
references.citation: Clin Microbiol Rev. 2001 Jan;14(1):114-28
references.pmid: 11148005
references.citation: J Infect Dis. 1979 Dec;140(6):984-8
references.pmid: 541526
references.citation: Am J Clin Nutr. 2001 Feb;73(2 Suppl):444S-450S
references.pmid: 11157355
references.citation: Can J Microbiol. 2011 Feb;57(2):127-35
references.pmid: 21326354
references.citation: Dig Dis Sci. 2008 Oct;53(10):2671-9
references.pmid: 18306038